Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Pla, Alessandra Fiorio ^a,b,c   Brossa, Alessia ^a   Bernardini, Michela ^a   Genova, Tullio ^a   Grolez, Guillaume ^b,c   Villers, Arnaud ^d   Leroy, Xavier ^e   Prevarskaya, Natalia ^b,c   Gkika, Dimitra ^b,c   Bussolati, Benedetta ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Université des Sciences et Technologies de Lille   (France)

^c Laboratory of Excellence in Ion Channel Science and Therapeutics   (France)

^d UNIV LILLE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Androgen receptor; Anti angiogenic therapy; Drug resistance; Prostate cancer; VEGF receptor

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; PROTEIN KINASE B; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL ISOLATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG EFFECT; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84928720989     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-939     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics 2012. CA Cancer J Clin 2012, 62:10-29.
2. Keizman D, Maimon N, Gottfried M: Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions. Am J Clin Oncol 2012. Epub ahead of print.
3. Godoy AS, Chung I, Montecinos VP, Buttyan R, Johnson CS, Smith GJ: Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate. Am J Physiol Endocrinol Metab 2013, 304:E1131-E1139.
4. Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H: Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int 2012, 110:E794-E808.
5. Antonarakis ES, Carducci MA: Targeting angiogenesis for the treatment of prostate cancer. Expert OpinTher Targets 2012, 16:365-376.
6. Blanc J, Geney R, Menet C: Type II kinase inhibitors: an opportunity in cancer for rational design. Anticancer Agents Med Chem 2013, 13:731-747.
7. Baluk P, Hashizume H, McDonald DM: Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005, 15:102-111.
8. Hida K, Hida Y, Shindoh M: Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008, 99:459-466.
9. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M: Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004, 64:8249-8255.
10. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G: Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003, 17:1159-1161.
11. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW: Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006, 108:2339-2348.
12. Dudley AC, Klangsbrun M: Tumor endothelial cells have features of adult stem cells. Cell Cycle 2009, 8:236-238.
13. Bussolati B, Grange C, Camussi G: Tumor exploits alternative strategies to achieve vascularization. FASEB J 2001, 25:2874-2882.
14. Bussolati B, Grange C, Bruno S, Buttiglieri S, Deregibus MC, Tei L, Aime S, Camussi G: Neural-Cell Adhesion Molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp Cell Res 2006, 312:913-924.
15. Fonsato V, Buttiglieri S, Deregibus MC, Puntorieri V, Bussolati B, Camussi G: Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis, resistance and angiogenesis. Am J Pathol 2006, 168:706-713.
16. Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY: Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009, 15:4838-4846.
17. Dudley AC, Khan ZA, Shih SC, Kang SY, Zwaans BM, Bischoff J, Klagsbrun M: Calcification of multipotent prostate tumor endothelium. Cancer Cell 2008, 14:201-211.
18. Grange C, Bussolati B, Bruno S, Fonsato V, Sapino A, Camussi G: Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep 2006, 15:381-386.
19. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G: Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007, 110:2440-2448.
20. Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, Skryma R, Prevarskaya N: Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. J Clin Invest 2007, 117:1647-1657.
21. Fiorio Pla A, Maric D, Brazer SC, Giacobini P, Liu X, Chang YH, Ambudkar IS, Barker JL: Canonical transient receptor potential 1 plays a role in basic fibroblast growth factor (bFGF)/FGF receptor-1-induced Ca2+ entry and embryonic rat neural stem cell proliferation. J Neurosci 2005, 25:2687-2701.
22. Zaborowska M, Szmit S, Szczylik C: Sorafenib in progressive castrateresistant prostate cancer. can we talk about a new therapeutic option? Arch Med Sci 2012, 8:528-532.
23. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE: Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010, 21:319-324.
24. Castellano D, González-Larriba JL, Antón-Aparicio LM, Cassinello J, Grande E, Esteban E, Sepúlveda J: Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. J Expert Opin Pharmacother 2011, 12:2433-2439.
25. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, Wang L, Wikner C, Qi JH, Wernstedt C, Wu J, Bruheim S, Mugishima H, Mukhopadhyay D, Spurkland A, Claesson-Welsh L: VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 2005, 24:2342-2353.
26. Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ: Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 2008, 149:2959-2969.
27. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
28. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD: IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011, 17:2538-2548.
29. Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis T: Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis 2012, 3:e262.
30. Grover AC, Tangrea MA, Woodson KG, Wallis BS, Hanson JC, Chuaqui RF, Gillespie JW, Erickson HS, Bonner RF, Pohida TJ, Emmert-Buck MR, Libutti SK: Tumor-associated endothelial cells display GSTP1 and RAR beta2 promoter methylation in human prostate cancer. J Transl Med 2006, 4:13.
31. Luo W, Hu Q, Wang D, Deeb KK, Ma Y, Morrison CD, Liu S, Johnson CS, Trump DL: Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue. Oncotarget 2013, 4:1472-1483.
32. Martínez-Jabaloyas JM, March-Villalba JA, Navarro-García MM, Dasi F: Antiangiogenic therapies in prostate cancer. Expert Opin Biol Ther 2013, 13:1-5.
33. Dror Michaelson M, Oudard S, Ou Y, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I: Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone versus prednisone alone in men with progressive metastatic castration-resistant prostate cancer. J ClinOncol 2014, 32(2):76-82.
34. Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg D, Hochhaus A, Hanauske AR, Edler L, Burkholder I, Scheulen M: A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007, 97:1480-1527.
35. Dahut WL, Scripture C, Posadas E, Ain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD:A Phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008, 14:209-214.
36. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL: Final analysis of a phase II trialusing sorafenib for metastaticcastration-resistant prostate cancer. BJU Int 2009, 103:1636-1640.
37. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR: Phase II study of sunitinib in men withadvanced prostate cancer. Ann Oncoln 2009, 20:913-920.
38. Dib E, Maia M, Lima Ade S, de Paula Fiod Costa E, de Moraes-Filho MN, Rodrigues EB, Penha FM, Coppini LP, de Barros NM, Coimbra Rde C, Magalhães Júnior O, Guerra T, Furlani Bde A, Freymuller E, Farah ME: In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinibmalate. Curr Eye Res 2012, 37:567-574.
39. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV: Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 2010, 29:2938-2949.
40. Bayyoud T, Hofmann J, Spitzer M, Bartz-Schmidt KU, Yoeruek E: Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells. Curr Eye Res 2013, 39:149-154.
41. Bussolati B, Assenzio B, Deregibus MC, Camussi G: The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med 2006, 84:852-863.
42. Beardsley EK, Hotte SJ, North S, Ellard SL, Winquist E, Kollmannsberger C, Mukherjee SD, Chi KN: A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs 2012, 30:1652-1659.